SGLT-2 inhibitors in patients with and without a history of heart failure: a meta-analysis
Victor Razuk(Mount Sinai Hospital), George Dangas(Mount Sinai Hospital), Roxana Mehran(Mount Sinai Hospital), David Power(Cardiovascular Institute of the South), Anne H. Tavenier(Cardiovascular Institute of the South), Anton Camaj(Columbia University Irving Medical Center), Johny Nicolas(Cardiovascular Institute of the South), Mauro Chiarito(Humanitas University), Davide Cao(Cardiovascular Institute of the South), Frans Beerkens(Icahn School of Medicine at Mount Sinai), Carlo Andrea Pivato(Cardiovascular Institute of the South)
Cited by 1
Related Papers
Clinical End Points in Coronary Stent Trials
|Circulation|2007|5.4k
From Vulnerable Plaque to Vulnerable Patient
|Circulation|2003|2.7k
From Vulnerable Plaque to Vulnerable Patient
|Circulation|2003|2.3k
Genetic Risk, Adherence to a Healthy Lifestyle, and Coronary Disease
|New England Journal of Medicine|2016|1.5k